简介：
Overview
This article describes a procedure to evaluate the in vivo behavior of cancer nanomedicines in tumor-bearing immunocompetent mice. The method assesses nanomedicine accumulation at systemic, tissue, single-cell, and subcellular levels, aiding in the identification of promising candidates for clinical translation.
Key Study Components
Area of Science
- Nanomedicine
- Cancer research
- In vivo imaging
Background
- Understanding in vivo performance of nanomedicines is crucial for clinical translation.
- Current techniques lack comprehensive evaluation methods.
- Dual-labeling approaches enhance characterization of nanomedicines.
- Liposomes serve as a common platform for experimental nanomedicines.
Purpose of Study
- To evaluate how nanomedicines accumulate in different tissues over time.
- To provide a method for in vivo characterization from macroscopic to microscopic levels.
- To demonstrate the procedure using liposomes as an example.
Methods Used
- Dissolve 20 mg of a lipid mixture with a fluorescent dye in chloroform.
- Utilize a dual-labeling approach for in vivo characterization.
- Assess accumulation of nanomedicines in tumor-bearing mice.
- Evaluate performance at systemic, tissue, single-cell, and subcellular levels.
Main Results
- The method allows for quantitative assessment of nanomedicine accumulation.
- Characterization spans from macroscopic to microscopic levels.
- Demonstrated effectiveness using liposomes in clinical use.
- Provides insights into the in vivo behavior of cancer nanomedicines.
Conclusions
- This procedure can help identify promising cancer nanomedicines for clinical use.
- Enhances understanding of nanomedicine behavior in living organisms.
- Supports the advancement of nanomedicine research and development.
What is the main goal of this procedure?
The main goal is to evaluate the in vivo behavior of cancer nanomedicines in tumor-bearing mice.
Why are liposomes chosen for this study?
Liposomes are currently in clinical use and serve as a common platform for experimental nanomedicines.
What levels are assessed in this evaluation?
The evaluation assesses systemic, tissue, single-cell, and subcellular levels.
How does the dual-labeling approach benefit the study?
It allows for comprehensive in vivo characterization from macroscopic to microscopic levels.
What insights does this procedure provide?
It provides insights into the accumulation and behavior of nanomedicines in living organisms.
How can this research impact clinical translation?
It may help identify promising candidates for clinical translation in cancer treatment.
繁體中文
